SmarTrend identified an Uptrend for Fibrogen Inc (NASDAQ:FGEN) on June 16th, 2020 at $39.74. In approximately 3 months, Fibrogen Inc has returned 5.51% as of today's recent price of $41.93.
FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Percy Carter, MBA, PhD, to the newly-created position of Chief Scientific Officer, where he will lead FibroGen's research efforts, leveraging...
Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shares down.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FGEN, BYND, LLY, BAC, and TSLA.
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences:
FibroGen (FGEN) is nearing a support level. Will it fall to $40? Learn when to enter a short position. Over the past couple of months a key support level was formed in the chart of FibroGen Inc. (...
Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $42.23 to a high of $44.87. Yesterday, the shares fell 4.6%, which took the trading range below the 3-day low of $43.77...
FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids...
FibroGen (FGEN) delivered earnings and revenue surprises of -61.02% and 22.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- Strong Second Quarter China Roxadustat Net Sales of $15.7 million -
- Appoints Aoife Brennan, M.B., B.Ch., President and CEO of Synlogic Inc. (NASDAQ:SYBX) -
Global investment firm KKR today announced that, following the completion of the voluntary tender offer period by Valorous Asia Holdings (the "Offeror"), an entity owned by KKR investment funds, the Offeror...
Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.
FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.
Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $42.58 to a high of $43.84. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $42.30...
FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients...
FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen's commercialization efforts, leveraging more...
Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $39.82 to a high of $41.15. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $40.63...
FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.
